<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867607</url>
  </required_header>
  <id_info>
    <org_study_id>MRX6-201ver4-HMO-CTIL</org_study_id>
    <nct_id>NCT00867607</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis</brief_title>
  <official_title>A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Morria Biopharmaceuticals PLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of
      Three Weeks of Daily Dermal Application of MRX-6 or steroid on the Treatment of Mild to
      Moderate Allergic Contact Dermatitis of the Hand and Forearm.

      Total number of patients: up to 80.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of three dose levels of topical MRX-6 (0.2%, 1.0% and 2% HyPE) when administered twice daily (b.i.d.) for 21 consecutive days</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in percentage change in each subject's total Physician's Visual Assessment (PVA) score from Baseline to Day 21 between the vehicle and MRX-6 treated hands/forearms.</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Allergic Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>MRX-6 (2%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX-6 (1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX-6 (0.2%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX-6</intervention_name>
    <description>b.i.d treatment for 21 days</description>
    <arm_group_label>MRX-6 (2%)</arm_group_label>
    <arm_group_label>MRX-6 (1%)</arm_group_label>
    <arm_group_label>MRX-6 (0.2%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid</intervention_name>
    <description>b.i.d. 21 days</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult men and women between 18 and 65 years old.

          2. Male or non-pregnant female subjects who agree to comply with applicable contraceptive
             requirements of the protocol. Details on potential child-bearing status, methods to
             regularly exclude pregnancy throughout the study and acceptable forms of contraception
             are provided in Section 3.4.1 of the protocol.

          3. Satisfactory medical assessment with no clinically significant and relevant
             abnormalities (of medical history, physical examination, clinical or laboratory
             evaluation [hematology, biochemistry, urinalysis]) as determined by the Principal
             Investigator, that might interfere with the assessment of the subjects dermatitis or
             the assessment of the safety or efficacy of the Study Drug.

          4. The subject must understand and be able, willing and likely to fully comply with study
             procedures and restrictions.

          5. Subject can understand and provide written informed consent to participate in the
             study, in accordance with the International Conference on Harmonisation (ICH) Good
             Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any
             study-related procedures listed in Section 5.1.1 of the protocol.

          6. Subject has mild to moderate bilateral allergic contact dermatitis on each hand,
             possibly extending to the forearm, according to Physicians Visual Assessment as
             described in Section 5.2.1 of the protocol. Mild to moderate disease is considered a
             PVA score of 10 or greater and there should be no more than a 1-point difference
             between hands.

          7. Have a + reaction to the Standard European Series patch testing kit (Chemotechnique
             Diagnostics Products, Malmo, Sweden) after application for 2 days, as described in
             Section 5.2.2 of the protocol.

        Exclusion Criteria:

          1. Current or recurrent disease that could affect the action, absorption or disposition
             of the Study Drug, or clinical or laboratory assessments.

          2. Have used topical antihistamines in the past 2 weeks, topical corticosteroids or
             received Psoralen plus ultra violet light therapy (PUVA) in the past 4 weeks, or have
             taken oral retinoids, corticosteroids in the past 8 weeks (inhaled or intranasal
             corticosteroids are allowed, if stable dose).

          3. Use of any prescription or OTC medication (excluding hormonal contraceptive, hormonal
             replacement therapy, inhaled or intranasal corticosteroids , or oral NSAIDs) that, in
             the opinion of the Principal Investigator, could affect (improve or worsen) the
             condition being studied, or could affect the action, absorption or disposition of the
             Study Drug, or clinical or laboratory assessments.

          4. Patients must not have used another investigational product or taken part in a
             clinical trial within the last 30 days prior to enrolment.

          5. Female patients who are pregnant or lactating, including females with a positive
             pregnancy test at screening, must be excluded.

          6. The subject known to have a positive hepatitis virus test (Hepatitis B virus surface
             antigen or hepatitis C virus antibody) or a positive human immunodeficiency virus
             (HIV) antibody test.

          7. A history of hypersensitivity to any of the Study Drugs or their excipients.

          8. Subject has any other significant dermatological condition that affects &gt;10% of the
             body surface area or general medical condition that could interfere with the study
             evaluation

          9. Subject has any significant medical condition that could compromise immune
             responsiveness

         10. Subject has a history of alcoholism or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Ramot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah university hospital, Jerusalem Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Hadassah Hospital</name>
      <address>
        <city>Ein Karem, Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dermatology department, Hadassah university hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.hadassah.org.il/English/Eng_SubNavBar/Departments/Medical+departments/Dermatology/</url>
    <description>Department of Dermatology at Hadassah Hospital</description>
  </link>
  <results_reference>
    <citation>Ingber A, Cohen Y, Krimsky M, Yedgar S. A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.</citation>
    <PMID>17346444</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact dermatitis</keyword>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

